These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12603918)

  • 1. Prostate cancer: metastatic.
    Michaelson MD; Talcott JA; Smith MR
    Clin Evid; 2002 Dec; (8):881-90. PubMed ID: 12603918
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormonal treatment of advanced disease: some newer aspects.
    Griffiths K; Eaton CL; Harper ME; Turkes A; Peeling WB
    Semin Oncol; 1994 Oct; 21(5):672-87. PubMed ID: 7939755
    [No Abstract]   [Full Text] [Related]  

  • 5. [Metastatic prostate carcinoma].
    Smith MR; Kantoff P; Talcott J
    Praxis (Bern 1994); 2001 Sep; 90(38):1653-8. PubMed ID: 11675919
    [No Abstract]   [Full Text] [Related]  

  • 6. The questionable use of hormone therapy in advanced carcinoma of the prostate.
    Murphy GP; Slack NH
    Urol Clin North Am; 1980 Oct; 7(3):631-8. PubMed ID: 6161459
    [No Abstract]   [Full Text] [Related]  

  • 7. [Complex treatment of prostate cancer patients].
    Sviridova TV; Dunchik VN; Mardynskiĭ IuS; Tsodikova LB
    Urol Nefrol (Mosk); 1984; (2):9-13. PubMed ID: 6719653
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental and theoretical basis for hormonal treatment of prostatic cancer.
    Carter HB; Isaacs JT
    Semin Urol; 1988 Nov; 6(4):262-8. PubMed ID: 3068765
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of quality of life in patients with prostate cancer.
    Fosså SD; Aass N; Opjordsmoen S
    Semin Oncol; 1994 Oct; 21(5):657-61. PubMed ID: 7524156
    [No Abstract]   [Full Text] [Related]  

  • 10. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials.
    Nanda A; D'Amico AV
    BJU Int; 2008 Nov; 102(10):1366-8. PubMed ID: 18778343
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues.
    Tolis G; Koutsilieris M; Stellos A; Fazekas AT; Klioze S; Yakabow A; Adenauer H
    Acta Endocrinol Suppl (Copenh); 1984; 265():22-3. PubMed ID: 6437108
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pro and contra -- adjuvant therapy in locoregional advanced prostatic carcinoma after radical prostatectomy].
    Ohlmann C; Heidenreich A
    Aktuelle Urol; 2004 Sep; 35(5):372-4. PubMed ID: 15478268
    [No Abstract]   [Full Text] [Related]  

  • 16. [Metastatic prostate cancer].
    Droz JP; Flechon A; Terret C
    Rev Prat; 2003 Dec; 53(20):2258-62. PubMed ID: 15018080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurosurgical management of endocrine dependent neoplasms.
    Parent AD
    J Miss State Med Assoc; 1979 Mar; 20(3):45-8. PubMed ID: 84875
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
    Shulman MJ; Benaim EA
    Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of hormone-resistant prostate cancer.
    Gibbons RP
    Prog Clin Biol Res; 1989; 303():337-45. PubMed ID: 2674995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.